11/28
08:00 am
sxtp
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its price target lowered by analysts at Ascendiant Capital Markets from $3.00 to $2.80. They now have a "buy" rating on the stock.
Low
Report
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its price target lowered by analysts at Ascendiant Capital Markets from $3.00 to $2.80. They now have a "buy" rating on the stock.
11/21
08:01 am
sxtp
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
Low
Report
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
11/20
06:03 am
sxtp
60 Degrees Pharmaceuticals (NASDAQ:SXTP) was upgraded by analysts at Zacks Research to a "hold" rating.
Neutral
Report
60 Degrees Pharmaceuticals (NASDAQ:SXTP) was upgraded by analysts at Zacks Research to a "hold" rating.
11/14
08:09 am
sxtp
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
High
Report
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
11/13
02:09 pm
sxtp
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results [Yahoo! Finance]
Low
Report
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results [Yahoo! Finance]
11/13
01:51 pm
sxtp
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
Low
Report
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
10/15
07:14 am
sxtp
60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
High
Report
60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
10/9
07:31 am
sxtp
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study [Yahoo! Finance]
Low
Report
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study [Yahoo! Finance]
10/9
07:04 am
sxtp
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
Medium
Report
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
10/2
02:05 am
sxtp
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
9/16
01:31 am
sxtp
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.